Incretin Analog Containing Compositions And Uses Thereof

Abstract: A composition is provided that includes an incretin analog having activity at each the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors (i.e., tri-receptor agonist) and one or more additional agents such as a tonicity agent and a preservative. Methods also are provided for treating diseases such as type 2 diabetes mellitus, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and obesity with the composition.

Patent Information

Application #

Filing Date

09 October 2023

Publication Number

37/2024

Publication Type

INA

Invention Field

CHEMICAL

Status

Email

Parent Application

Applicants

ELI LILLY AND COMPANY

Lilly Corporate Center Indianapolis, Indiana 46285

Inventors

1. GOPALRATHNAM, Ganapathy

c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, Indiana 46206-6288

2. MINIE, Christopher Sears

c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, Indiana 46206-6288

Specification

Documents

Application Documents

#	Name	Date
1	202317067510-STATEMENT OF UNDERTAKING (FORM 3) [09-10-2023(online)].pdf	2023-10-09
2	202317067510-Sequence Listing in txt [09-10-2023(online)].txt	2023-10-09
3	202317067510-Sequence Listing in PDF [09-10-2023(online)].pdf	2023-10-09
4	202317067510-REQUEST FOR EXAMINATION (FORM-18) [09-10-2023(online)].pdf	2023-10-09
5	202317067510-PROOF OF RIGHT [09-10-2023(online)].pdf	2023-10-09
6	202317067510-POWER OF AUTHORITY [09-10-2023(online)].pdf	2023-10-09
7	202317067510-FORM 18 [09-10-2023(online)].pdf	2023-10-09
8	202317067510-FORM 1 [09-10-2023(online)].pdf	2023-10-09
9	202317067510-DECLARATION OF INVENTORSHIP (FORM 5) [09-10-2023(online)].pdf	2023-10-09
10	202317067510-COMPLETE SPECIFICATION [09-10-2023(online)].pdf	2023-10-09
11	202317067510-FORM-26 [10-10-2023(online)].pdf	2023-10-10
12	202317067510-FORM 3 [03-04-2024(online)].pdf	2024-04-03